- Home
- PTN
PTN
Palatin Technologies Inc.
as 04-23-2025 4:00pm EST
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | CRANBURY |
| Market Cap: | N/A | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $2.48 | Next Earning Date: | 05-14-2025 |
| Revenue: | $350,000 | Revenue Growth: | -95.07% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palatin Technologies Inc. News
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
MT Newswires
10 days ago
Top Premarket Gainers
PR Newswire
10 days ago
Palatin Appeals NYSE American Notice of Delisting
MT Newswires
12 days ago
Top Midday Decliners
MT Newswires
13 days ago
Palatin Technologies Gets Delisting Notice from NYSE American, Plans to Appeal
PR Newswire
13 days ago
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
PR Newswire
14 days ago
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
PR Newswire
24 days ago
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Compare PTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.